• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Elutia raises $26M for drug-eluting biomatrix tech

September 19, 2023 By Sean Whooley

Elutia LogoElutia (Nasdaq:ELUT) announced today that it entered into a securities purchase agreement worth total proceeds of $26.2 million.

The drug-eluting biomatrix company expects the private placement financing to result in initial gross proceeds of approximately $10.5 million. The full exercise of warrants would add $15.8 million to reach a total of $26.2 million.

Silver Spring, Maryland-based Elutia expects the cash raised to support the advancement of its drug-eluting biomatrix products. The company also expects the divestiture of its orthobiologics business to aid in the effort. Elutia develops its drug-eluting products for the pacemaker and defibrillator market, plus breast reconstruction post-mastectomy.

The company designed its CanGaroo Envelope for device protection with acellular biologic material. The porcine small intestine submucosa extracellular matrix creates a healthy pocket for implanted devices. Its Simpliderm pre-hydrated human acellular dermal matrix supports soft tissue repair in breast reconstruction. It enhances and supports the angiogenic process, providing a more pliable matrix. The implant results in a lower risk of inflammatory response, fast integration and rapid revascularization.

Existing investor HighCape Capital and new investors Nantahala Capital and a life-sciences-focused investment fund participated. Lake Street Capital Markets acts as the exclusive placement agent. Elutia expects the transaction to close on Sept. 21, subject to certain conditions.

“We appreciate the support of our investors, demonstrating the high value of our platforms and technology for patient care,” said Dr. Randy Mills, president and CEO of Elutia. “The combined proceeds from our orthobiologics divestiture and today’s financing potentially adds more than $60 million in cash to our balance sheet, materially strengthening our financial position and extending our cash runway. We remain well-positioned to execute on our upcoming program milestones involving CanGaroo for device protection and SimpliDerm for breast reconstruction.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Implants, Regenerative Medicine, Stem Cells Tagged With: Elutia

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS